XEN45 Gel Stent Combined with Healaflow Injectable Viscoelastic Implant.

IF 0.7 Q4 OPHTHALMOLOGY
Case Reports in Ophthalmological Medicine Pub Date : 2023-11-22 eCollection Date: 2023-01-01 DOI:10.1155/2023/7096406
Eloy Villarreal, Eran Berkowitz, Beatrice Tiosano
{"title":"XEN45 Gel Stent Combined with Healaflow Injectable Viscoelastic Implant.","authors":"Eloy Villarreal, Eran Berkowitz, Beatrice Tiosano","doi":"10.1155/2023/7096406","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To introduce a potential solution for failed glaucoma surgeries by proposing an optional surgical procedure in conjunction with the use of Healaflow (Anteis S.A., Geneva, Switzerland) as a spacer, which may potentially reduce the failure rate. <i>Case Presentation</i>. We present the outcomes of a surgical procedure involving the inferonasal implantation of an ab interno XEN gel stent (Allergan, Dublin, Ireland) in a 74-year-old male patient who was experiencing uncontrolled advanced glaucoma in his left eye. It is important to note that the patient had previously undergone several glaucoma surgeries and procedures in the same eye. During this particular procedure, we utilized Healaflow as a spacer by implanting the stent within a subconjunctival Healaflow \"bubble.\" At 6 months postoperatively, intraocular pressure remained on target. There was no need for additional topical medications, and no change in visual acuity was observed.</p><p><strong>Conclusion: </strong>For patients with a history of unsuccessful glaucoma surgeries and who are unsuitable candidates for tube shunt procedures or transscleral diode cyclophotocoagulation, an alternative option involves implanting the XEN45 stent in the inferior nasal region in conjunction with the use of subconjunctival Healaflow. This combined approach may provide a potential solution for managing glaucoma in these patients.</p>","PeriodicalId":9603,"journal":{"name":"Case Reports in Ophthalmological Medicine","volume":"2023 ","pages":"7096406"},"PeriodicalIF":0.7000,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686706/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Ophthalmological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/7096406","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To introduce a potential solution for failed glaucoma surgeries by proposing an optional surgical procedure in conjunction with the use of Healaflow (Anteis S.A., Geneva, Switzerland) as a spacer, which may potentially reduce the failure rate. Case Presentation. We present the outcomes of a surgical procedure involving the inferonasal implantation of an ab interno XEN gel stent (Allergan, Dublin, Ireland) in a 74-year-old male patient who was experiencing uncontrolled advanced glaucoma in his left eye. It is important to note that the patient had previously undergone several glaucoma surgeries and procedures in the same eye. During this particular procedure, we utilized Healaflow as a spacer by implanting the stent within a subconjunctival Healaflow "bubble." At 6 months postoperatively, intraocular pressure remained on target. There was no need for additional topical medications, and no change in visual acuity was observed.

Conclusion: For patients with a history of unsuccessful glaucoma surgeries and who are unsuitable candidates for tube shunt procedures or transscleral diode cyclophotocoagulation, an alternative option involves implanting the XEN45 stent in the inferior nasal region in conjunction with the use of subconjunctival Healaflow. This combined approach may provide a potential solution for managing glaucoma in these patients.

XEN45凝胶支架联合Healaflow可注射粘弹性种植体。
目的:为青光眼手术失败提供一种潜在的解决方案,提出一种可选的手术方法,结合使用Healaflow (Anteis s.a., Geneva, Switzerland)作为间隔剂,这可能会潜在地降低失败率。案例演示。我们报告一例74岁男性左眼青光眼不受控制的鼻间植入ab interno XEN凝胶支架(Allergan, Dublin, Ireland)的手术结果。值得注意的是,该患者此前曾在同一只眼睛进行过多次青光眼手术和手术。在这个特殊的手术中,我们将Healaflow支架植入结膜下Healaflow“气泡”中,作为间隔物。术后6个月,眼压保持正常。不需要额外的局部药物治疗,也没有观察到视力的变化。结论:对于有青光眼手术失败史且不适合进行管分流术或经巩膜二极管光凝术的患者,另一种选择包括在下鼻区植入XEN45支架并使用结膜下healflow。这种联合方法可能为治疗这些患者的青光眼提供一种潜在的解决方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
38
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信